ProQR Therapeutics (NASDAQ:PRQR) Receives Average Rating of "Buy" from Analysts

Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have been given a consensus recommendation of "Buy" by the six ratings firms that are currently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $8.83.

PRQR has been the topic of several research analyst reports. Raymond James raised ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their price objective for the company from $6.00 to $14.00 in a research report on Tuesday, October 29th. StockNews.com downgraded ProQR Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, November 28th. Chardan Capital reaffirmed a "buy" rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Finally, Oppenheimer initiated coverage on ProQR Therapeutics in a research report on Friday, January 10th. They issued an "outperform" rating and a $15.00 price objective on the stock.

ProQR Therapeutics Stock Performance

Shares of PRQR traded up $0.13 during mid-day trading on Friday, hitting $2.25. 341,586 shares of the stock were exchanged, compared to its average volume of 353,398. The company has a market cap of $183.78 million, a PE ratio of -7.03 and a beta of 0.30. ProQR Therapeutics has a 52-week low of $1.61 and a 52-week high of $4.62. The firm has a 50-day moving average of $2.77 and a two-hundred day moving average of $2.57.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01. The firm had revenue of $4.22 million for the quarter, compared to the consensus estimate of $4.75 million. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. On average, sell-side analysts predict that ProQR Therapeutics will post -0.31 EPS for the current year.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds have recently made changes to their positions in the stock. Privium Fund Management B.V. boosted its position in shares of ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company's stock worth $10,251,000 after purchasing an additional 51,663 shares in the last quarter. OneDigital Investment Advisors LLC boosted its position in shares of ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 15,550 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 7,300 shares in the last quarter. Finally, Ballentine Partners LLC acquired a new stake in shares of ProQR Therapeutics in the 4th quarter worth $61,000. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).